| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5663159 | GILEAD | Prodrugs of phosphonates |
Sep, 2014
(9 years ago) | |
| US6451340 | GILEAD | Nucleotide analog compositions |
Jul, 2018
(5 years ago) | |
Hepsera is owned by Gilead.
Hepsera contains Adefovir Dipivoxil.
Hepsera has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Hepsera are:
- US5663159
- US6451340
Hepsera was authorised for market use on 20 September, 2002.
Hepsera is available in tablet;oral dosage forms.
Hepsera can be used as therapy in chronic hepatitis b virus infection.
The generics of Hepsera are possible to be released after 23 July, 2018.
Drugs and Companies using ADEFOVIR DIPIVOXIL ingredient
Market Authorisation Date: 20 September, 2002
Treatment: Therapy in chronic hepatitis b virus infection
Dosage: TABLET;ORAL
How can I launch a generic of HEPSERA before it's drug patent expiration?
More Information on Dosage
HEPSERA family patents
